Location
Moultrie, GA
Start Date
4-5-2022 1:00 PM
End Date
4-5-2022 4:00 PM
Description
Multisystem inflammatory syndrome in children (MIS-C) is a severe hyperinflammatory condition characterized by fever, systemic inflammation, and multiorgan dysfunction that manifests late in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). MIS-C generally occurs 2 to 6 weeks after SARS-CoV-2 infection. The incidence of MIS-C is unknown, although it appears to occur in less than 1 percent of children with confirmed SARS-CoV-2 infection. MIS-C has overlapping clinical features of toxic shock syndrome and Kawasaki disease, although the pathogenesis is unclear. Epidemiologists, researchers, and clinicians are struggling to describe and characterize the disease phenomenon while treating patients at the forefront. We describe a case of MIS-C in a previously healthy 2-year-old female who presented to the emergency department with fever, abdominal pain, vomiting, reduced oral intake, generalized skin rash, and cardiogenic shock associated with COVID-19. Additionally, she was found to have acute kidney injury and mild transaminitis. She was diagnosed as MIS-C on the basis of clinical and laboratory criteria. She improved after receiving intravenous immunoglobulin (IVIG), high dose IV steroids, Lovenox for elevated D-dimers, and other supportive therapy without any complications. This case report adds to the literature on MIS-C, which is important among the medical community as prior knowledge can help communities quickly identify and treat affected patients.
Included in
COVID-19 in Children: A Pediatric Case of Multisystem Inflammatory Syndrome and Shock
Moultrie, GA
Multisystem inflammatory syndrome in children (MIS-C) is a severe hyperinflammatory condition characterized by fever, systemic inflammation, and multiorgan dysfunction that manifests late in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). MIS-C generally occurs 2 to 6 weeks after SARS-CoV-2 infection. The incidence of MIS-C is unknown, although it appears to occur in less than 1 percent of children with confirmed SARS-CoV-2 infection. MIS-C has overlapping clinical features of toxic shock syndrome and Kawasaki disease, although the pathogenesis is unclear. Epidemiologists, researchers, and clinicians are struggling to describe and characterize the disease phenomenon while treating patients at the forefront. We describe a case of MIS-C in a previously healthy 2-year-old female who presented to the emergency department with fever, abdominal pain, vomiting, reduced oral intake, generalized skin rash, and cardiogenic shock associated with COVID-19. Additionally, she was found to have acute kidney injury and mild transaminitis. She was diagnosed as MIS-C on the basis of clinical and laboratory criteria. She improved after receiving intravenous immunoglobulin (IVIG), high dose IV steroids, Lovenox for elevated D-dimers, and other supportive therapy without any complications. This case report adds to the literature on MIS-C, which is important among the medical community as prior knowledge can help communities quickly identify and treat affected patients.